Opportunity within Cytotoxic Drugs and HPAPI Manufacturing Market Expected to Grow at ~12% Annual Rate, Through 2035, Says Roots Analysis

Root analysis

Driven by the potential treatment of the root cause of diseases, including rare clinical conditions and those previously thought to be incurable, the gene therapy pipeline is growing and the market forecasts substantial growth, through 2030

London, Nov. 21, 2022 (GLOBE NEWSWIRE) — Root analysis announced the addition of “HPAPI and Cytotoxic Drug Manufacturing Market (4th edition), 2022 – 2035” refer to his offer list.

The production of highly potent compounds is a laborious procedure beset by various challenges, including high capital investment, extensive operational experience, as well as access to advanced infrastructure and technologies. As a result, outsourcing has become a preferred business model in this industry, providing greater flexibility, reduced costs, and timely drug launches. Additionally, to keep pace with evolving customer requirements, several contract manufacturing organizations have upgraded their existing capabilities/facilities.

To order this 330+ page report, which features over 100 figures and over 160 tables, visit

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Main market information

More than 140 companies say they offer contract manufacturing services of highly potent active pharmaceutical ingredients (HPAPI) and cytotoxic drugs, globally
The majority (44%) of industry stakeholders are based in Europe, followed by those based in North America (35%). Additionally, over 30% of service providers say they have the capabilities to produce both HPAPI and highly potent finished dosage forms. It is also worth mentioning that over 50% of the players offer contract manufacturing services for HPAPI and cytotoxic drugs across all three scales of operation.

About 35% of partnership agreements were signed after 2020
Most deals related to cytotoxic drug contract manufacturing were seen as instances of acquisitions, accounting for 21% of total partnerships. Furthermore, most of the intercontinental deals, as well as intracontinental ones, have been inked by players based in Europe.

More than 95 expansion initiatives have been observed since 2018
Approximately 50% of initiatives focused on expanding existing high potency compound manufacturing facilities, followed by capacity expansions (27%) and new facility additions (24%). Over 65% of the expansions reported in this domain were local initiatives, followed by international initiatives (33%).

Globally installed HPAPI contract manufacturing capacity is currently estimated at over 2.5 million litres
The maximum share (83%) of the current installed capacity is expected to be captured by very large operators. In addition, nearly 40% of global installed manufacturing capacity is available with facilities located in the Europe region.

North America and Europe are expected to capture over 70% market share by 2035
The Asia Pacific market is likely to grow at a relatively faster pace (12.8%) over the long term. Currently, the majority share (62%) of the overall cytotoxic and HPAPI production market is captured by HPAPIs; this trend is unlikely to change in the foreseeable future as well. Furthermore, in 2035, more than 80% of the market share is likely to be captured by highly potent small molecules.

To request a sample/booklet copy of this report, please visit

https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

Answers to key questions

  • Who are the key players involved in offering Cytotoxic Drug Contract Manufacturing Services and HPAPI Manufacturing?

  • What are the current opportunities within the HPAPI and Cytotoxic Drugs market?

  • What is the relative competitiveness of HPAPI and cytotoxic drug contract manufacturers?

  • What types of partnership models are commonly adopted by stakeholders in this industry?

  • What are the different types of expansion initiatives undertaken by HPAPI and cytotoxic drug contract manufacturers?

  • What are the main challenges faced by HPAPI and cytotoxic drug contract manufacturers?

  • What are the major market trends and driving factors that could impact this market?

  • How is the revenue generation potential associated with cytotoxic drugs and HPAPI manufacturing market likely to evolve in the coming years?

The financial opportunity within the HPAPI and Cytotoxic Drugs Manufacturing Market has been analyzed into the following segments:

Product type

Company size

  • Small

  • Medium sized

  • Large

  • Very wide

Operating scale

  • Preclinical

  • Clinical

  • Commercial

Type of molecule

Highly potent finished dosage form type

  • Injectables

  • Oral solids

  • Creams

  • Other

Major geographic regions

  • North America (United States, Canada and Mexico)

  • Europe (UK, Italy, Germany, France, Spain and Rest of Europe)

  • Asia-Pacific (China, India and Rest of Asia-Pacific)

  • Rest of the world

The report also features contributions from eminent industry stakeholders, according to whom, the continued growth of oncology therapeutics pipeline and growing preference for outsourcing is likely to drive the growth of the overall HPAPI and cytotoxic drug manufacturing market, in the foreseeable future. . The report includes detailed transcripts of discussions held with the following experts:

  • Justin Mason-Home (owner and director, HPAPI Project Service)

  • Antonella Mancuso and Maria Elena Guadagno (Vice President and Chief Operating Officer and Business Director, BSP Pharmaceuticals)

  • Scott Patterson (Vice President of Pharmaceutical/Bio Technical Support, ILC Dover)

  • Stacy McDonald and Jennifer L. Mitcham (former group product manager and former director of business development); Abul Khair (Business Development Associate, Catalent)

  • Roberto Margarita (Director of Business Development, CordenPharma)

  • Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)

  • Kevin Rosenthal (Former Commercial Director, Formulations and Finished Products, Alphora Research (acquired by Eurofins))

  • Mark Wright (Former Site Head, Grangemouth, Piramal)

  • Allison Vavala (Former Senior Manager, Business Development, Helsinn)

  • Valentino Mandelli (Head of Marketing and Sales, Pharma, Cerbios-Pharma)

  • Javier E. Aznarez Araiz (Ex-Business Development, Idifarma)

The search includes profiles of key players (listed below); each profile presents a brief overview of the company, details related to its financial performance (if available), recent developments and an informed future perspective.

For more details, please visit
https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

  1. Biopharmaceutical contract manufacturing Market: Global Industry Trends and Forecasts, 2022-2035

  2. Third party production ADC Market (5th Edition): Industry Trends and Global Forecasts, 2022-2035

  3. Gene therapy Market: Global Industry Trends and Forecasts, 2022-2035

  4. Continuous production (small molecules and biological products) Market (2nd Edition): Industry Trends and Global Forecasts, 2022-2035

  5. Peptide Therapeutics: Contract API manufacturing Market: Global Industry Trends and Forecasts, 2022-2035

  6. Freeze-drying services market for biopharmaceuticals: Global Industry Trends and Forecasts, 2022-2035

  7. Contract manufacturing of nanoparticles (pay attention to lipid and metal nanoparticles) Market: Global Industry Trends and Forecasts, 2021-2035

CONTACT: Gaurav Chaudhary gaurav.chaudhary@rootsanalysis.com Roots Analysis A430, 4th Floor, Bestech Business Towers, Sector 66, Mohali, India sales@rootsanalysis.com +1 (415) 800 3415 +44 (122) 391 1091 Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis

Leave a Reply

%d bloggers like this: